# South Korea Hemostasis Tissue Sealing Agents Market > South Korea Hemostasis Tissue Sealing Agents Market Research Report: By Product Type (Topical Hemostat, Adhesive & Tissue Sealant), By Material (Chitosan-based Products, Mineral based Products), By Application (Trauma, General Surgery, Minimally Invasive Surgery, Gynaecology, Others) andBy End User (Hospitals, Ambulatory Surgical Centers, Research Institutes) - Growth & Industry Forecast 2025 To 2035 South Korea Hemostasis Tissue Sealing Agents Market Overview: As per MRFR analysis, the South Korea Hemostasis Tissue Sealing Agents Market Size was estimated at 209 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.31% - **2024:** $ 226 Million - **2025:** $ 244.78 Million - **2035:** $ 544 Million - **Key Players:** Johnson & Johnson (US), Baxter International (US), Medtronic (US), Stryker Corporation (US), C.R. Bard (US), Ethicon (US), Terumo Corporation (JP), B. Braun Melsungen AG (DE), Hemostasis, Inc. (US) **Report ID:** MRFR/HC/48034-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-hemostasis-tissue-sealing-agents-market-49790 --- ## Market Summary ## **South Korea Hemostasis Tissue Sealing Agents Market Overview** As per MRFR analysis, the South Korea Hemostasis Tissue Sealing Agents Market Size was estimated at 209.75 (USD Million) in 2023. The South Korea Hemostasis Tissue Sealing Agents Market Industry is expected to grow from 225.5(USD Million) in 2024 to 573.8 (USD Million) by 2035. The South Korea Hemostasis Tissue Sealing Agents Market CAGR (growth rate) is expected to be around 8.861% during the forecast period (2025 - 2035). ### **Key South Korea Hemostasis Tissue Sealing Agents Market Trends Highlighted** The South Korea Hemostasis Tissue Sealing Agents Market is witnessing significant growth driven by several key market drivers. One of the primary factors is the increasing number of surgical procedures performed in the country, which has amplified the demand for effective hemostatic solutions. The South Korean healthcare system is advanced and continues to invest in innovative medical technologies, thereby enhancing surgical outcomes and reducing complications associated with bleeding. Furthermore, a rising prevalence of chronic diseases requiring surgical intervention and an aging population are propelling the demand for these agents. Opportunities in the South Korean market can be explored through the development of novel hemostatic agents with improved efficacy and safety profiles. Tissue bio-based and synthetic sealing agents are of increasing interest, which is in line with the sustainable healthcare vision of South Korea. Moreover, the partnership of research institutes with healthcare corporations is likely to enhance the innovation of products and fulfill particular clinical requirements. Nowadays, the market is witnessing changes, such as the shift towards invasive surgery due to improvements in surgical instruments and the expansion of surgical techniques. This shift improves the need for specially designed hemostatic agents for such procedures. South Korean market, which still focuses on patient care and recovery, makes it a necessity to have products that aid in fast recovery and reduce hospital stays, which fuels the need in the market. As hospitals and surgical centers focus on efficiency and patient safety, the development and adoption of advanced hemostasis tissue sealing agents will likely continue to trend upward in South Korea. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Hemostasis Tissue Sealing Agents Market Drivers** ### **Growing Surgical Procedures** The increasing number of surgical procedures being performed in South Korea is a significant driver contributing to the growth of the South Korea Hemostasis Tissue Sealing Agents Market Industry. According to the Korea National Health Insurance Service, there has been a rise in elective surgeries and minimally invasive procedures, with recorded surgical operation numbers reaching over 4 million annually in recent years. This upward trend corresponds to a greater demand for effective hemostasis and tissue sealing agents during these procedures. Organizations such as the Korean Society of Surgery are continuously promoting advances in surgical technologies, including hemostatic agents, which further supports this growth. With the advancement of techniques and technology, the demand for quality sealing agents that assure patient safety and minimize complications post-surgery is likely to increase, catalyzing market growth significantly. ### **Advancements in Medical Technology** Advancements in medical technology and the development of innovative hemostasis agents are among the key drivers for the South Korea Hemostasis Tissue Sealing Agents Market Industry. With ongoing Research and Development efforts, companies like Medtronic and Johnson & Johnson have introduced advanced tissue sealing agents that offer enhanced performance and safety. As reported by the Ministry of Health and Welfare of South Korea, the growth rate of technological investment in healthcare has increased by approximately 15% annually, leading to the introduction of minimally invasive solutions. This improvement not only enhances surgical outcomes but also boosts the adoption rates of these agents across hospitals and surgical centers, thereby accelerating the market's growth. ### **Increasing Prevalence of Chronic Diseases** The rising prevalence of chronic diseases, especially cardiovascular and cancer-related conditions in South Korea, has substantially impacted the South Korea Hemostasis Tissue Sealing Agents Market Industry. Studies indicate that the number of cancer patients in South Korea has surged to over 240,000 in recent years, as detailed by the Korea Central Cancer Registry. This increase in diseases requiring surgery necessitates the use of effective hemostatic solutions, driving demand. Furthermore, institutions such as the Korean Cancer Association are actively involved in research and providing insights into treatment methodologies that rely on advanced tissue sealing techniques, thereby fostering market growth. ## **South Korea Hemostasis Tissue Sealing Agents Market Segment Insights** ### **Hemostasis Tissue Sealing Agents Market Product Type Insights** The South Korea Hemostasis Tissue Sealing Agents Market, particularly within the Product Type segment, demonstrates a robust expansion trajectory, influenced by various factors such as technological advancements, an increasing elderly population, and a rising demand for surgical procedures. The market is significantly segmented into three main Product Types: Topical Hemostat, Adhesive, and Tissue Sealant. Topical Hemostats play a crucial role in managing bleeding during surgical interventions, reflecting their growing usage in trauma and surgical scenarios. Innovations in formulations and delivery systems have enhanced their effectiveness, leading to greater adoption in medical practices. Adhesives are also notable within this market, providing strong bonding properties that facilitate tissue repair and closure. They are favored for their ease of application and versatility in a range of surgical procedures, from orthopedic surgeries to cardiac interventions. The growing emphasis on minimally invasive surgical techniques further amplifies the usage of adhesive products, as they often contribute to reduced recovery times and improved patient outcomes. Tissue Sealants, on the other hand, represent another vital component of the South Korea Hemostasis Tissue Sealing Agents Market, especially in complex surgeries where achieving hemostasis is critical. These sealants not only control bleeding but also promote tissue adhesion and healing, thereby addressing a wide array of medical needs across specialties like cardiovascular and plastic surgery. The continuous evolution in sealant formulations is anticipated to enhance their safety and efficiency, making them indispensable in modern surgical environments. Overall, the Product Type segment of the South Korea Hemostasis Tissue Sealing Agents Market not only reflects the industry's growth potential but also highlights significant advancements that align with the growing complexities of medical procedures. As healthcare continues to evolve, the focus on innovative solutions within this market segment will likely result in an increase in adoption rates among healthcare providers, thereby driving further advancements in patient care in South Korea. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Hemostasis Tissue Sealing Agents Market Material Insights** The South Korea Hemostasis Tissue Sealing Agents Market, particularly focusing on the Material segment, reflects a growing demand due to advancements in surgical procedures and a significant increase in patient populations requiring effective hemostatic solutions. The segment includes prominent categories such as Chitosan-based Products and Mineral-based Products, both of which hold notable significance within the market. Chitosan-based Products are recognized for their excellent biocompatibility and ability to enhance wound healing, making them a preferred choice in various surgical applications. Similarly, Mineral-based Products are valued for their natural properties enabling efficient clotting processes, which are crucial in addressing surgical challenges effectively. The rising prevalence of surgeries in South Korea, supported by a robust healthcare infrastructure and increasing investments in Research and Development, is expected to drive the innovation and adoption of these materials. As the market develops, both segments are positioned to play essential roles in improving patient outcomes, ultimately contributing to the overall growth of the South Korea Hemostasis Tissue Sealing Agents Market. ### **Hemostasis Tissue Sealing Agents Market Application Insights** The South Korea Hemostasis Tissue Sealing Agents Market is diverse, with significant applications across various medical fields. The Trauma segment plays a vital role due to the increasing incidence of injuries that necessitate effective hemostatic solutions. General Surgery is another critical area, utilizing these agents to enhance surgical outcomes by reducing blood loss during procedures. Minimally Invasive Surgery is rapidly gaining traction as advancements in technology drive the demand for effective sealing agents that ensure patient safety while minimizing recovery time. Gynecology also accounts for substantial usage, as hemostatic agents are crucial in managing surgical procedures unique to women's health. Additionally, other applications within the market encompass a range of uses, further broadening the scope of hemostatic technologies. Collectively, these segments highlight the growing importance of hemostasis tissue sealing agents in South Korea's healthcare system, buoyed by a focus on improved surgical techniques and patient outcomes. The increasing healthcare expenditure and technological innovations further bolster this market, driving its expansion across the diverse applications mentioned. ### **Hemostasis Tissue Sealing Agents Market End User Insights** The South Korea Hemostasis Tissue Sealing Agents Market, particularly within the End User segment, comprises key areas such as Hospitals, Ambulatory Surgical Centers, and Research Institutes, each playing a critical role in the overall landscape. Hospitals are increasingly adopting advanced sealing agents for various surgical procedures, driven by the demand for improved patient outcomes and reduced recovery times. Ambulatory Surgical Centers are growing in popularity due to the preference for outpatient procedures, where quick and efficient hemostasis is vital. They often serve patients requiring less invasive interventions, thus necessitating effective sealing solutions. Research Institutes amplify innovation within the market by focusing on developing and testing new hemostatic products, contributing to enhanced healthcare practices. Together, these sectors reflect the growing importance of Hemostasis Tissue Sealing Agents in South Korea's healthcare system, driven by trends such as technological advancement, increased surgical volume, and an aging population, further propelling the demand for effective sealing solutions across these end users. ## **South Korea Hemostasis Tissue Sealing Agents Market Key Players and Competitive Insights** The competitive landscape of the South Korea Hemostasis Tissue Sealing Agents Market is characterized by a blend of established players and emerging companies. This market has seen significant growth due to the rising demand for surgical procedures and the ongoing advancements in medical technologies that enhance operational efficiency and patient outcomes. Competitive insights reveal that companies are implementing strategic partnerships and collaborations to enhance their product offerings while focusing on innovation to meet regulatory standards. Moreover, the market is influenced by factors such as the increasing geriatric population, rising incidence of surgeries, and a growing emphasis on minimally invasive procedures. As companies strive to capture market share, they are also investing in research and development to introduce advanced hemostasis tissue sealing agents that cater to specific surgical requirements. Integra LifeSciences has established a robust presence in the South Korean Hemostasis Tissue Sealing Agents Market, showcasing strengths in the development and commercialization of innovative surgical products that address the needs of healthcare professionals and patients. With a focus on providing effective hemostatic solutions, Integra LifeSciences has garnered a reputable position in the market, building trust through consistent quality and reliability. Their product lines, which are designed for various surgical applications, exhibit cutting-edge technology that enhances surgical outcomes. Furthermore, Integra LifeSciences actively engages in educational initiatives for surgeons and clinical professionals, thereby solidifying its reputation as a knowledgeable leader in the field. This commitment to excellence and a deep understanding of local market dynamics empower Integra LifeSciences to effectively serve the South Korean market. B. Braun holds a significant position in the South Korea Hemostasis Tissue Sealing Agents Market, recognized for its comprehensive range of medical and surgical products. The company's strengths lie in its innovation-driven approach and established distribution network, which enable efficient delivery of its products to healthcare facilities across the region. B. Braun's portfolio includes advanced hemostatic agents designed to facilitate surgical procedures while minimizing complications. The company's commitment to research and development allows it to stay ahead of emerging trends and enhance its product lineup periodically. In addition to its strong market presence, B. Braun has engaged in various mergers and acquisitions that have bolstered its capabilities and market reach in South Korea. These strategic moves reflect the company’s dedication to expanding its influence in the healthcare sector while continuously evolving its offerings to meet the needs of surgical environments. ### **Key Companies in the South Korea Hemostasis Tissue Sealing Agents Market Include** ## **South Korea Hemostasis Tissue Sealing Agents Market Industry Developments** In recent months, the South Korea Hemostasis Tissue Sealing Agents Market has been active with several developments. In September 2023, Integra LifeSciences announced a significant increase in its product offerings, focusing on advanced hemostatic agents to cater to the growing demand for surgical procedures across the country. B. Braun also expanded its portfolio by launching a new line of tissue sealing products, targeting minimally invasive surgeries and enhancing their position in the market. Additionally, Medtronic reported a successful partnership with local entities in August 2023 aimed at enhancing patient outcomes through innovative sealing technologies. The market valuation has witnessed a positive trend, with a reported growth rate of over 6% in the last two years, reflecting an increased adoption of advanced hemostasis solutions in hospitals. Furthermore, there were notable collaborations, such as Baxter International’s strategic partnership with local healthcare providers in June 2023 to enhance market penetration. Companies like Ethicon and Stryker Corporation are also actively investing in Research and Development to innovate solutions tailored for the South Korean healthcare landscape, solidifying their market presence amid rising competition. ## **South Korea Hemostasis Tissue Sealing Agents Market Segmentation Insights** ### **Hemostasis Tissue Sealing Agents Market Product Type Outlook** ### **Hemostasis Tissue Sealing Agents Market Material Outlook** ### **Hemostasis Tissue Sealing Agents Market Application Outlook** ### **Hemostasis Tissue Sealing Agents Market End User Outlook** - Hospitals - Ambulatory Surgical Centers - Research Institutes ## Market Drivers ### Rising Surgical Procedures The increasing number of surgical procedures in South Korea is a pivotal driver for the hemostasis tissue-sealing-agents market. As the healthcare sector expands, the demand for effective hemostatic solutions rises correspondingly. In 2025, surgical procedures are projected to increase by approximately 5% annually, leading to a heightened need for advanced tissue-sealing agents. This trend is particularly evident in areas such as orthopedic and cardiovascular surgeries, where effective hemostasis is critical. The hemostasis tissue-sealing-agents market is likely to benefit from this surge, as hospitals and surgical centers seek reliable products to minimize bleeding and enhance patient outcomes. Furthermore, the integration of these agents into standard surgical protocols may further solidify their role in modern surgical practices. ### Increased Focus on Patient Safety The growing emphasis on patient safety and quality of care is a crucial driver for the hemostasis tissue-sealing-agents market. Healthcare providers in South Korea are increasingly prioritizing products that enhance surgical outcomes and reduce complications. This focus is reflected in the rising adoption of hemostatic agents that minimize blood loss and promote faster recovery times. In 2025, it is estimated that hospitals will allocate up to 15% of their surgical budgets towards advanced hemostatic solutions. The hemostasis tissue-sealing-agents market is positioned to capitalize on this trend, as healthcare institutions seek to implement best practices that align with patient safety initiatives and regulatory standards. ### Advancements in Medical Technology Technological advancements in medical devices and surgical techniques are significantly influencing the hemostasis tissue-sealing-agents market. Innovations such as minimally invasive surgery and robotic-assisted procedures necessitate the use of advanced sealing agents that can provide effective hemostasis with minimal tissue trauma. In South Korea, the adoption of these technologies is on the rise, with a projected market growth of 7% in the next few years. This growth is likely to drive demand for hemostatic agents that are compatible with new surgical methodologies. The hemostasis tissue-sealing-agents market must adapt to these changes by developing products that meet the evolving needs of healthcare providers, ensuring that they remain at the forefront of surgical innovation. ### Growing Awareness of Hemostasis Solutions There is a notable increase in awareness regarding the benefits of hemostasis solutions among healthcare professionals in South Korea. This heightened awareness is driving demand for effective tissue-sealing agents, as surgeons and medical staff recognize the importance of managing bleeding during surgical procedures. Educational initiatives and training programs are contributing to this trend, with an estimated 20% increase in workshops focused on hemostatic techniques over the past year. The hemostasis tissue-sealing-agents market stands to gain from this growing knowledge base, as informed practitioners are more likely to adopt advanced sealing agents that enhance surgical efficiency and patient outcomes. ### Regulatory Support for Innovative Products Regulatory bodies in South Korea are increasingly supportive of innovative medical products, which is beneficial for the hemostasis tissue-sealing-agents market. Streamlined approval processes and incentives for research and development are encouraging manufacturers to introduce novel hemostatic agents. In 2025, it is anticipated that regulatory approvals for new products will increase by 10%, fostering a competitive environment that drives innovation. This regulatory landscape allows the hemostasis tissue-sealing-agents market to thrive, as companies can bring cutting-edge solutions to market more efficiently, ultimately improving surgical practices and patient care. ## Future Outlook The [Hemostasis Tissue Sealing Agents Market](https://www.marketresearchfuture.com/reports/hemostasis-tissue-sealing-agents-market-7559) is projected to grow at an 8.31% CAGR from 2025 to 2035, driven by technological advancements and increasing surgical procedures. **New opportunities:** - Development of biodegradable tissue-sealing agents for enhanced patient safety. - Expansion into outpatient surgical centers to capture new market segments. - Partnerships with hospitals for exclusive supply agreements to secure market share. By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare demands. ## Segment Insights ### By Product: Topical Hemostat (Largest) vs. Adhesive & Tissue Sealant (Fastest-Growing) In the South Korea hemostasis tissue-sealing-agents market, the distribution of market share reveals that Topical Hemostat holds a substantial position due to its widespread application in surgical settings. This segment dominates the market, benefiting from a well-established presence among healthcare providers, which favors its use for effective bleeding control. Meanwhile, the Adhesive & Tissue Sealant segment, while currently smaller in share, is quickly gaining traction due to advancements in technology and increased adoption in various medical procedures. Growth trends indicate a robust increase in the demand for Adhesive & Tissue Sealants driven by innovation and enhanced performance characteristics. Factors such as the rising number of surgeries and an expanding patient population are propelling this segment towards becoming a crucial player in the market. As healthcare professionals seek efficient and reliable solutions, investment in research and development is likely to enhance the offerings and improve market penetration for these products. Topical Hemostat (Dominant) vs. Adhesive & Tissue Sealant (Emerging) Topical Hemostat is recognized as the dominant product in the South Korea hemostasis tissue-sealing-agents market, leveraging its extensive use in surgical procedures due to its rapid action and reliability in controlling hemorrhage. This segment has established a strong customer base, highlighting its effectiveness in trauma care and elective surgeries. On the other hand, Adhesive & Tissue Sealant is emerging quickly, characterized by its versatility and ability to bond tissues. These products cater to a variety of applications such as wound closure and organ adhesion. The shift towards minimally invasive surgical techniques has further enhanced the appeal of these adhesives, making them increasingly essential in modern surgical practices. ### By Material: Chitosan-based Products (Largest) vs. Mineral based Products (Fastest-Growing) In the South Korea hemostasis tissue-sealing-agents market, Chitosan-based Products constitute the largest share due to their extensive application in surgical settings and wound care management. These products are favored for their biocompatibility and effective hemostatic properties, appealing to both healthcare providers and patients alike. On the other hand, Mineral based Products are gaining traction, which highlights an increasing acceptance in advanced surgical procedures due to their unique characteristics and formulation benefits. Growth trends in the South Korea hemostasis tissue-sealing-agents market show a significant uptick in demand for Mineral based Products as healthcare professionals seek innovative solutions for wound management. The rise in surgical procedures, along with growing healthcare expenditure, is propelling the growth of this segment. Additionally, the emphasis on minimizing postoperative complications and enhancing patient recovery times spurs advancements in product formulations, making Mineral based Products increasingly attractive for medical applications. Chitosan-based Products (Dominant) vs. Mineral based Products (Emerging) Chitosan-based Products hold a dominant position in the South Korea hemostasis tissue-sealing-agents market due to their natural origin and proven efficacy in promoting hemostasis. Their biocompatibility minimizes side effects, making them a preferred choice in various surgical applications. In contrast, Mineral based Products are emerging as a competitive alternative, showing innovative formulations that cater to specific clinical needs. With unique properties that enhance performance, they are becoming increasingly popular in hospitals and clinics. The shift towards these emerging products is driven by the medical community's continuous quest for advanced materials that not only provide effective sealing but also support healing and minimize infection risks. ### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the South Korea hemostasis tissue-sealing-agents market, hospitals are the largest end user segment, commanding a significant share due to the high volume of surgical procedures performed. Their adoption of advanced hemostasis agents is driven by the demand for effective solutions to manage bleeding during complex surgeries. In contrast, ambulatory surgical centers are emerging rapidly, benefiting from the increasing trend towards outpatient procedures, which require efficient and innovative sealing agents to minimize bleeding risks and enhance patient recovery. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals are the dominant players in the South Korea hemostasis tissue-sealing-agents market, utilizing these agents extensively in various surgical specialties such as orthopedics, cardiology, and general surgery. Their large-scale operations enable them to invest significantly in the latest hemostatic technologies, ensuring improved patient outcomes. On the other hand, ambulatory surgical centers represent an emerging segment. These centers focus on outpatient procedures where the need for rapid recovery is critical. They are adopting innovative hemostatic products at a rapid pace, driven by increasing patient preference for minimally invasive surgeries and the need for faster discharge times. ## Competitive Benchmarking The hemostasis tissue-sealing-agents market in South Korea exhibits a dynamic competitive landscape, characterized by a blend of innovation and strategic partnerships among key players. Major companies such as Johnson & Johnson (US), Baxter International (US), and Medtronic (US) are at the forefront, leveraging their extensive research and development capabilities to enhance product offerings. Johnson & Johnson (US) focuses on expanding its portfolio through innovative solutions, while Baxter International (US) emphasizes strategic collaborations to enhance its market presence. Medtronic (US) appears to be concentrating on digital transformation initiatives to streamline operations and improve patient outcomes, collectively shaping a competitive environment that prioritizes technological advancement and customer-centric solutions.The market structure is moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. This fragmentation allows for a diverse range of products and services, catering to various surgical needs. Companies are increasingly localizing their manufacturing processes to reduce costs and improve supply chain efficiency, which is crucial in maintaining competitive pricing and ensuring timely delivery of products. In October Baxter International (US) announced a strategic partnership with a leading South Korean medical device firm to co-develop advanced hemostatic agents tailored for local surgical practices. This collaboration is expected to enhance Baxter's market penetration in South Korea, allowing for the introduction of innovative products that meet specific regional demands. Such partnerships not only bolster product offerings but also signify a commitment to understanding and addressing local healthcare needs. In September Medtronic (US) launched a new line of tissue-sealing agents that integrate AI technology to optimize surgical procedures. This launch is pivotal as it positions Medtronic as a leader in the integration of advanced technologies within the hemostasis market. The incorporation of AI is likely to enhance surgical precision and reduce recovery times, thereby improving overall patient outcomes and solidifying Medtronic's competitive edge. In August Johnson & Johnson (US) expanded its manufacturing capabilities in South Korea, investing approximately $50 million in a new facility dedicated to the production of hemostatic agents. This investment underscores the company's commitment to meeting the growing demand for advanced surgical solutions in the region. By increasing local production capacity, Johnson & Johnson (US) aims to enhance supply chain reliability and reduce lead times, which are critical factors in the competitive landscape. As of November current trends in the hemostasis tissue-sealing-agents market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, enhanced supply chain reliability, and sustainable practices. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in an increasingly competitive environment. ## Recent News & Developments In recent months, the South Korea Hemostasis Tissue Sealing Agents Market has been active with several developments. In September 2023, Integra LifeSciences announced a significant increase in its product offerings, focusing on advanced hemostatic agents to cater to the growing demand for surgical procedures across the country. B. Braun also expanded its portfolio by launching a new line of tissue sealing products, targeting minimally invasive surgeries and enhancing their position in the market. Additionally, Medtronic reported a successful partnership with local entities in August 2023 aimed at enhancing patient outcomes through innovative sealing technologies. The market valuation has witnessed a positive trend, with a reported growth rate of over 6% in the last two years, reflecting an increased adoption of advanced hemostasis solutions in hospitals. Furthermore, there were notable collaborations, such as Baxter International’s strategic partnership with local healthcare providers in June 2023 to enhance market penetration. Companies like Ethicon and Stryker Corporation are also actively investing in Research and Development to innovate solutions tailored for the South Korean healthcare landscape, solidifying their market presence amid rising competition. ## Report Scope | MARKET SIZE 2024 | 226.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 244.78(USD Million) | | MARKET SIZE 2035 | 544.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.31% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Johnson & Johnson (US), Baxter International (US), Medtronic (US), Stryker Corporation (US), C.R. Bard (US), Ethicon (US), Terumo Corporation (JP), B. Braun Melsungen AG (DE), Hemostasis, Inc. (US) | | Segments Covered | Product, Material, End User | | Key Market Opportunities | Advancements in biocompatible materials enhance efficacy in the hemostasis tissue-sealing-agents market. | | Key Market Dynamics | Rising demand for advanced hemostasis tissue-sealing agents driven by regulatory support and technological innovations in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the hemostasis tissue-sealing-agents market in South Korea?** A: The market valuation was $226.0 Million in 2024. **Q: What is the projected market size for hemostasis tissue-sealing agents by 2035?** A: The market is expected to reach $544.0 Million by 2035. **Q: What is the expected CAGR for the South Korea hemostasis tissue-sealing-agents market during the forecast period?** A: The expected CAGR is 8.31% from 2025 to 2035. **Q: Which product segment had the highest valuation in 2024?** A: The Adhesive & Tissue Sealant segment had a valuation of $136.0 Million in 2024. **Q: What are the two main material segments in the hemostasis tissue-sealing-agents market?** A: The main material segments are Chitosan-based Products and Mineral based Products. **Q: What was the valuation of Chitosan-based Products in 2024?** A: Chitosan-based Products had a valuation of $90.0 Million in 2024. **Q: Which end user segment is projected to grow the most by 2035?** A: The Hospitals segment is projected to grow to $220.0 Million by 2035. **Q: Who are the key players in the South Korea hemostasis tissue-sealing-agents market?** A: Key players include Johnson & Johnson, Baxter International, and Medtronic, among others. **Q: What was the valuation of the Ambulatory Surgical Centers segment in 2024?** A: The Ambulatory Surgical Centers segment had a valuation of $70.0 Million in 2024. **Q: What is the projected valuation for Mineral based Products by 2035?** A: Mineral based Products are projected to reach $328.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-hemostasis-tissue-sealing-agents-market-49790*